Engineering actin-resistant human DNase I for treatment of cystic fibrosis.
Human deoxyribonuclease I (DNase I), an enzyme recently approved for treatment of cystic fibrosis (CF), has been engineered to create two classes of mutants: actin-resistant variants, which still catalyze DNA hydrolysis but are no longer inhibited by globular actin (G-actin) and active site variants...
Kaydedildi:
| Yayımlandı: | Proc Natl Acad Sci U S A |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
National Academy of Sciences
1996
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC38651/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8710851/ https://ncbi.nlm.nih.govhttps://doi.org/10.1073/pnas.93.16.8225 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|